ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has ...

“This expanded collaboration with MSD, a world leader in vaccine development and commercialization, is truly transformative for Evaxion. It provides strong validation of our AI-Immunology ...

Under the terms of the agreement, MSD gains non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets. The agreement also grants MSD the option to ...

InvestingPro Insights As Evaxion Biotech (NASDAQ: EVAX) advances its vaccine collaboration with MSD, investors are closely monitoring the company's financial health and stock performance.

Evaxion Biotech (EVAX) shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development collaboration with MSD (NYSE:MRK) (tradename of ...

MSD obtains a Non-Exclusive License for Cyprumed's delivery technology to develop oral peptide therapeutics Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory ...

Orion's collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women's cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of ...

“This expanded collaboration with MSD, a world leader in vaccine development and commercialization, is truly transformative for Evaxion. It provides strong validation of our AI-Immunology™ platform ...

“We are excited to expand our collaboration with Evaxion with a focus on advancing EVX-B2 and EVX-B3 into clinical development.” Evaxion and MSD have been collaborating on EVX-B3 since 2023.

ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has expanded the ...